Archive
1250 articles, sorted by publication time.
CellCarta has brought together digital pathology, image analysis, liquid biopsy, and precision diagnostics companies in an effort to establish a comparable and verifiable pathway for pharmaceutical companies to adopt AI; however, the consortium has yet to disclose data scale, performance metrics, or actual clinical plans.
A retrospective study of 770 people across 17 countries found that skin reactions, neuropathy, and diarrhea were the most common severe adverse events associated with enfortumab vedotin; beyond efficacy, early recognition of toxicity is becoming key to maintaining treatment.
The collaboration, worth up to $110 million, shifts the focus of AI in drug discovery back to experimental data: Relation will use human disease cell models to generate multi-omics perturbation data, but model performance, disease scope, and the payment structure remain undisclosed.
Among more than 6,300 high-risk patients with cardiovascular and kidney disease, Novo Nordisk’s IL-6 antibody demonstrated the expected biological activity but failed to reduce cardiovascular death, myocardial infarction, or stroke; the full data and two other outcomes trials will determine the future of this anti-inflammatory approach.
This antisense oligonucleotide seeks to restore the UNC13A protein needed for neural signal transmission; two early-stage studies in the UK and Europe and in China are underway, but the first questions at this stage are safety and whether the drug can engage its biological target.
The approval brings a new option to some gastric cancer patients who have undergone multiple lines of treatment and demonstrates that CAR-T may be able to break through the barriers posed by solid tumors. However, its narrow eligible population, durability of efficacy, manufacturing burden, and price of nearly RMB 1 million will continue to shape its clinical impact.
From vials and prefilled syringes to autoinjectors, the FDA draft asks developers to examine differences in materials, operation, and labeling item by item; whether users can safely complete critical tasks will shape human factors evidence and interchangeability strategies.
A UK phase 3 trial involving 1,152 people showed that fatigue decreased across all groups during multidisciplinary care; comprehensive imaging brought no additional improvement, while digital rehabilitation produced only a modest difference at 24 weeks.
The FDA did not require additional clinical trials for GTx-104, but manufacturing-site compliance, packaging-component leachables data, and excipient risk assessments remain incomplete; the company is simultaneously remediating its original supply chain and bringing on a second U.S. facility.
An all-silicon MEMS sensor measured markedly different surface stiffness in ex vivo gastric tissues, offering a new direction for real-time tissue identification during surgery; however, the preliminary results from nine samples still require substantial engineering and validation before clinical navigation becomes feasible.
EmulatRx assigns trial planning, patient screening, clinical review, and causal analysis to five AI agents and simulated 20 studies using two real-world datasets; the results suggest it could accelerate early-stage decision-making, but it cannot yet replace randomized trials or professional oversight.
Insilico used multi-omics data to screen targets, then applied generative chemistry to design a small molecule capable of entering the brain. Animal studies have shown preliminary analgesic activity, but the target has not yet been disclosed, and evidence of efficacy and safety remains limited to the company’s announced preclinical findings.